528 related articles for article (PubMed ID: 11961505)
1. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
Sullivan JM; Pietras KM; Shin BJ; Misasi JN
Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
[TBL] [Abstract][Full Text] [Related]
2. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
[TBL] [Abstract][Full Text] [Related]
3. Ribozyme knockdown of the gamma-subunit of rod cGMP phosphodiesterase alters the ERG and retinal morphology in wild-type mice.
Liu J; Timmers AM; Lewin AS; Hauswirth WW
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3836-44. PubMed ID: 16186371
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach.
Gorbatyuk MS; Pang JJ; Thomas J; Hauswirth WW; Lewin AS
Mol Vis; 2005 Aug; 11():648-56. PubMed ID: 16145542
[TBL] [Abstract][Full Text] [Related]
5. An allele-specific hammerhead ribozyme gene therapy for a porcine model of autosomal dominant retinitis pigmentosa.
Shaw LC; Skold A; Wong F; Petters R; Hauswirth WW; Lewin AS
Mol Vis; 2001 Jan; 7():6-13. PubMed ID: 11172137
[TBL] [Abstract][Full Text] [Related]
6. Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.
O'Neill B; Millington-Ward S; O'Reilly M; Tuohy G; Kiang AS; Kenna PF; Humphries P; Farrar GJ
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2863-9. PubMed ID: 10967039
[TBL] [Abstract][Full Text] [Related]
7. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
[TBL] [Abstract][Full Text] [Related]
8. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa.
Lewin AS; Drenser KA; Hauswirth WW; Nishikawa S; Yasumura D; Flannery JG; LaVail MM
Nat Med; 1998 Aug; 4(8):967-71. PubMed ID: 9701253
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa.
Mendes HF; Cheetham ME
Hum Mol Genet; 2008 Oct; 17(19):3043-54. PubMed ID: 18635576
[TBL] [Abstract][Full Text] [Related]
10. Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.
Abdelmaksoud HE; Yau EH; Zuker M; Sullivan JM
Exp Eye Res; 2009 May; 88(5):859-79. PubMed ID: 19094986
[TBL] [Abstract][Full Text] [Related]
11. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA.
Scherr M; LeBon J; Castanotto D; Cunliffe HE; Meltzer PS; Ganser A; Riggs AD; Rossi JJ
Mol Ther; 2001 Nov; 4(5):454-60. PubMed ID: 11708882
[TBL] [Abstract][Full Text] [Related]
12. [Clone, expression and cleavage activity of anti-caspase-7 hammerhead ribozyme in vitro].
Zhang W; Xie Q; Zhou XQ; Jiang S; Jin YX
Zhonghua Gan Zang Bing Za Zhi; 2004 Nov; 12(11):684-7. PubMed ID: 15623380
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of cone opsin mRNA levels following experimental retinal detachment and reattachment.
Rex TS; Lewis GP; Geller SF; Fisher SK
Mol Vis; 2002 Apr; 8():114-8. PubMed ID: 11979236
[TBL] [Abstract][Full Text] [Related]
15. Novel cleavage of a hammerhead ribozyme targeted to beta-amyloid peptide precursor mRNA.
Denman R; Miller DL
Arch Biochem Biophys; 1993 Sep; 305(2):392-400. PubMed ID: 8373177
[TBL] [Abstract][Full Text] [Related]
16. Simulation of human autosomal dominant retinitis pigmentosa in transgenic mice expressing a mutated murine opsin gene.
Naash MI; Hollyfield JG; al-Ubaidi MR; Baehr W
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5499-503. PubMed ID: 8516292
[TBL] [Abstract][Full Text] [Related]
17. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells.
Spoerri PE; Afzal A; Li Calzi S; Shaw LC; Cai J; Pan H; Boulton M; Grant MB
Mol Vis; 2006 Jan; 12():32-42. PubMed ID: 16446700
[TBL] [Abstract][Full Text] [Related]
18. Cellular expression and siRNA-mediated interference of rhodopsin cis-acting splicing mutants associated with autosomal dominant retinitis pigmentosa.
Hernan I; Gamundi MJ; Planas E; Borràs E; Maseras M; Carballo M
Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3723-9. PubMed ID: 21357407
[TBL] [Abstract][Full Text] [Related]
19. Cloning and characterization of rod opsin cDNA from the Old World monkey, Macaca fascicularis.
Nickells RW; Burgoyne CF; Quigley HA; Zack DJ
Invest Ophthalmol Vis Sci; 1995 Jan; 36(1):72-82. PubMed ID: 7822161
[TBL] [Abstract][Full Text] [Related]
20. Factors altering ribozyme-mediated cleavage of tumor necrosis factor-alpha mRNA in vitro.
Kisich KO; Freedland SJ; Erickson KL
Biochem Biophys Res Commun; 1997 Jul; 236(1):205-11. PubMed ID: 9223453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
